Cybin D/B/A Helus Pharma
NASDAQ · us_market
No AI insight generated yet for this ticker.
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Citadel | multi-strat | 19.7K | $94.48K | 0.00% | Trimmed-99.6% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-06-25upcoming | -1.13 | — | — |
| 2026-02-13 | -0.81 | -1.36 | -68.33% |
| 2025-11-13 | -1.33 | -1.65 | -24.53% |
| 2025-08-13 | -1.10 | -0.97 | +11.98% |
| 2025-06-30 | -1.23 | -1.46 | -18.70% |
| 2025-02-10 | -1.57 | -0.53 | +66.19% |
| 2024-11-13 | -0.91 | -2.86 | -215.15% |
| 2024-08-08 | -1.33 | -0.76 | +42.86% |
| 2024-06-26 | -1.52 | -0.76 | +50.00% |
| 2024-02-14 | -1.37 | -3.42 | -150.00% |
| 2023-11-13 | -1.77 | -1.90 | -7.14% |
| 2023-08-14 | -2.13 | -2.66 | -25.00% |
| 2023-06-27 | -2.28 | -2.65 | -16.40% |
| 2023-02-14 | -2.66 | -2.28 | +14.29% |
| 2022-11-14 | -2.85 | -2.09 | +26.67% |
| 2022-08-08 | -3.29 | -2.75 | +16.35% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| HELP | -11.65% | -42.41% | -44.38% | -42.84% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -14.62% | -37.77% | -40.93% | -55.53% |